Hyoscine Butylbromide Milpharm Limited (Hyoscine Butylbromide)

The drug acts as a competitive antagonist at muscarinic acetylcholine receptors, especially the M3 subtype. By blocking these receptors, it reduces calcium‑mediated contraction of smooth muscle, leading to relaxation of the gastrointestinal tract and decreased spasm.

Dosage is individualized and should be determined by a qualified prescriber based on the patient’s condition, age, and response. Healthcare professionals consider clinical guidelines and patient factors when selecting the appropriate strength and frequency.

The pregnancy safety category for Hyoscine Butylbromide is not clearly defined. It should only be used during pregnancy or lactation if the potential benefit justifies any potential risk, and under the guidance of a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hyoscine Butylbromide is an anticholinergic agent, similar to drugs like dicyclomine or mebeverine. Compared with other classes, it provides rapid relief of smooth‑muscle spasm but may have a higher incidence of anticholinergic side effects such as dry mouth and blurred vision.

Store the product at temperatures below 25 °C, keeping it in the original packaging to protect from moisture. Avoid exposure to excessive heat or humidity, and keep the container tightly closed when not in use.

Hyoscine Butylbromide is administered orally. The tablet (or other oral dosage form) should be swallowed whole with a glass of water, unless otherwise directed by a healthcare professional.

Serious adverse reactions can include severe allergic responses such as anaphylaxis, acute angle‑closure glaucoma, paralytic ileus, and marked hypotension. Patients should seek immediate medical attention if they experience symptoms like swelling, difficulty breathing, or sudden vision changes.

Hyoscine Butylbromide is contraindicated in individuals with known hypersensitivity to the drug, those with narrow‑angle glaucoma, severe urinary retention, myasthenia gravis, or significant gastrointestinal obstruction. Consultation with a healthcare provider is essential before starting therapy.